An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2010
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 02 Oct 2009 Actual patient number (153) added as reported by ClinicalTrials.gov.
- 02 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.